Research Article
The Impact of Lipoprotein-Associated Oxidative Stress on Cell-Specific Microvesicle Release in Patients with Familial Hypercholesterolemia
Table 2
Plasma levels of circulating MVs.
| | | Controls () | FH () | value |
| | Total MVs | 15603 (10549–45211) | 35616 (23409–58075) | 0.022 | | Total CD36+ MVs | 2161 (1274–3213) | 2754 (1704–3772) | NS | | EMVs | 157 (119–238) | 282 (204–522) | 0.002 | | CD36+ EMVs | 143 (85–212) | 212 (170–408) | 0.008 | | PMVs | 2020 (1387–2876) | 1664 (1382–2773) | NS | | CD36+ PMVs | 1758 (1229–2475) | 1482 (1219–2482) | NS | | MMVs | 5 (3–11) | 10 (7–14) | 0.004 | | CD36+ MMVs | 3 (2–4) | 5 (4–8) | 0.001 | | ErytMVs | 207 (147–282) | 296 (193–453) | 0.043 | | CD36+ ErytMVs | 8 (3–13) | 11 (6–15) | NS | | TF+ MPs | 225 (204–396) | 408 (327–451) | 0.006 |
|
|
Values (MVs μL−1 plasma) are shown as the median (interquartile range). MVs, microvesicles; MMVs, monocyte-derived MVs; EMVs, endothelial cell-derived MVs; PMVs, platelet-derived MVs; ErytMVs, erythrocyte-derived MVs; CD36, scavenger receptor CD36; TF, tissue factor.
|
